Mr. Evan M. Levine is the President and Chief Executive Officer of Adventrx Pharmaceuticals Inc. since September 4, 2004. He also served as its Chief Operating Officer. Currently, Mr. Levine also serves as the Managing Member of Mark Capital, L.L.C. He has over 18 years of investment banking, venture capital, institutional trading, arbitrage dealing, and senior corporate management experience. From March 2002 to June 2002, Mr. Levine served as the Interim Chief Executive Officer of Digital Courier Technologies, Inc. From 1997 to 2001, he served as a Managing Principal and Portfolio Manager of Brown Simpson Asset Management. From 1996 to 1997, Mr. Levine served as a Senior Vice President of Convertible Sales and Trading at Dillon Read & Company. From 1993 to 1996, he served as a Vice President of Convertible Sales and Trading at Hambrecht & Quist. From 1992 to 1993, Mr. Levine served as a Global Arbitrage Trader at Spectrum Trading Partners. He is a Director at Quantrx Biomedical Corp. Mr. Levine also serves as a Member of Audit and Compensation Committees of Adventrx Pharmaceuticals Inc. and previously served as a Director since October 2002. He received a B.A. in Economics and Finance from Rutgers University and an M.B.A. from the New York University's Stern School of Business.
HTX Price at posting:
0.4¢ Sentiment: Hold Disclosure: Held